Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Haydock
As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.
Head of industry group in Japan makes personal plea at major biotech meeting for improvements to Japan’s innovation ecosystem, as government representatives say steps are already being taken to improve collaborative research and foster bioventures.
Emerging Company Profile: Newly formed Singapore venture DotBio aims to develop novel immuno-oncology therapies based on optimized, multi-specific humanized domain antibodies, with a focus on targeting checkpoint blockades, positive immune signals and tumor-specific processes in oncology.
With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.
Japan was never known for its healthcare-focused venture capital funds, but Whiz Partners, Inc. is looking to fill what it sees as a void, helped by some heavy corporate hitters, and a major new collaboration with Takeda's spun out preclinical development operations in Japan.
Japan's National Cancer Center is progressing a collaborative project with industry to encourage the development of targeted therapies for rare cancers, as part of wider efforts to support early access to personalized oncology drugs.